Compare · QDEL vs VRAX
QDEL vs VRAX
Side-by-side comparison of QuidelOrtho Corporation (QDEL) and Virax Biolabs Group Limited (VRAX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both QDEL and VRAX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- QDEL is the larger of the two at $656.6M, about 1147.8x VRAX ($572,047).
- Both names hit the wire about 4 times in the past 4 weeks.
- QDEL has more recent analyst coverage (19 ratings vs 1 for VRAX).
- Company
- QuidelOrtho Corporation
- Virax Biolabs Group Limited
- Price
- -
- -
- Market cap
- $656.6M
- $572,047
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- News (4w)
- 4
- 4
- Recent ratings
- 19
- 1
QuidelOrtho Corporation
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a POC products to detect infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, it offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, the company provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers Lyra molecular real-time polymerase chain reaction assays; Solana, an amplification and detection system; and Virena, a wireless cellular data management and surveillance system The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was incorporated in 1979 and is headquartered in San Diego, California.
Virax Biolabs Group Limited
Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company offers rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, and individual consumers. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. The company was incorporated in 2021 and is based in London, the United Kingdom.
Latest QDEL
- SEC Form SCHEDULE 13G filed by QuidelOrtho Corporation
- QuidelOrtho Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits
- QuidelOrtho Reports Third Quarter 2026 Financial Results
- Transforming Data Into Actionable Insights in the Lab
- QuidelOrtho to Report Third Quarter 2026 Financial Results on November 3, 2026
- SEC Form 4 filed by QuidelOrtho Corporation
- QuidelOrtho Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Amendment: SEC Form SCHEDULE 13G/A filed by QuidelOrtho Corporation
- QuidelOrtho Appoints Sanjeev Sharma as Vice President of Investor Relations
- Early Intervention Aids Emergency Medicine Teams in Identifying and Personalizing Sepsis Treatment
Latest VRAX
- SEC Form 6-K filed by Virax Biolabs Group Limited
- SEC Form 6-K filed by Virax Biolabs Group Limited
- SEC Form 6-K filed by Virax Biolabs Group Limited
- Virax Biolabs Appoints Three Distributors for ImmuneSelect Research Products in Mainland China
- SEC Form 3 filed by Virax Biolabs Group Limited
- SEC Form 6-K filed by Virax Biolabs Group Limited
- SEC Form 424B5 filed by Virax Biolabs Group Limited
- SEC Form EFFECT filed by Virax Biolabs Group Limited
- Amendment: SEC Form F-3/A filed by Virax Biolabs Group Limited
- SEC Form 6-K filed by Virax Biolabs Group Limited